Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of RSVpreF vaccine in adults aged 60 years and older
CTR20263340Phase 3Active
- Sponsor
- Pfizer
- Start
- Sep 2026
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of RSVpreF vaccine in respiratory syncytial virus disease (RSV), pulmonary infection, sponsored by Pfizer. Started Sep 2026; status: active.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus disease (RSV)pulmonary infection
Beyond the preview
Go deeper on CTR20263340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263340.